JSL
ALNY icon

JT Stratford LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

JT Stratford LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-737
Closed -$203K – 292
2024
Q3 		$203K Buy
+737
New +$192K 0.03% 277

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JT Stratford LLC's ALNY Position: Q4 2024 in Review

JT Stratford LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 737 shares — an estimated $203K sold.

JT Stratford LLC first reported a position in ALNY in Q3 2024 and held it in 1 quarter. The position peaked at $203K in Q3 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • JT Stratford LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • JT Stratford LLC sold 737 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $203K.
  • JT Stratford LLC first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • JT Stratford LLC's Alnylam Pharmaceuticals position peaked at $203K in Q3 2024.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on JT Stratford LLC's 13F filing for Q4 2024, filed 18 Feb 2025.